Graphite Bio pauses Phase 1/2 sickle cell gene therapy study after serious adverse event in first patient

LENZ Therapeutics, Inc.

First patient dosed with nula-cel experienced prolonged pancytopenia requiring ongoing transfusion and growth factor support.
Company will not meet guidance for initial proof-of-concept data in mid-2023; IND for GPH102 in beta-thalassemia delayed beyond mid-2024.
Company working to identify operational efficiencies to extend cash runway to at least 2026; will provide business update by end of Q1 2023.
Patient achieved neutrophil engraftment with no evidence of myelodysplasia; event reported to FDA.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.